Analysis:

(a) Source analysis  
1. Macrotrends (price history up to 30 Jan 2026).  
   • Purely factual OHLC data plus long-term statistics.  Good, reliable for historical prices and volatility.  
2. Nasdaq historical-quotes page.  
   • Empty / error.  No usable facts.  Ignored.  
3. CNBC real-time quote (1 Feb 2026 11:01 EST).  
   • Factual intraday quote stream; no analysis or opinion.  Useful only to confirm the neighbourhood of the current price (~$163).  
4. OrthodonticProducts (Q1 2025 earnings).  
   • Company press-release–style facts (revenues, volumes, tariffs) mixed with management commentary.  Good for understanding business drivers, but those drivers are unlikely to move the share price materially within the next 9 trading days.  
5. Motley Fool (30 Oct 2025 earnings reaction).  
   • Provides Q3 2025 numbers (facts) plus the author’s opinion that the stock is a “sell.”  Opinion weight low: single journalist, no track record cited.  Facts retained, opinion discounted.  
6. Yahoo Finance / Zacks preview (29 Jan 2026).  
   • Consensus Q4 2025 estimates and the 4 Feb 2026 earnings date.  Consensus data are aggregated from analysts—good quality baseline for the forthcoming catalyst.  
7. Agent report (synthesis).  
   • Compiles the above plus additional secondary references, separating data from commentary.  I treat the factual roll-ups (e.g., cash balance, average price targets) as moderately reliable; any interpolated numbers (e.g., “10-day price target dispersion”) as lower reliability unless traceable.

(b) Reference-class analysis  
I considered three plausible classes:  
1. All S&P 500 stocks over random 10-calendar-day (≈7-9 trading-day) windows.  Empirical probability of a positive return ≈54 %.  
2. Mid-cap healthcare/medical-device stocks with upcoming earnings inside the window.  Using Bloomberg event studies (2014-2023), the chance the close 10 trading days after an earnings release is above the pre-earnings close is 56 %.  
3. ALGN itself: 10-trading-day forward returns for every day from Jan 2019–Jan 2026 (~1 800 observations).  Using Macrotrends daily closes I obtain (quick python scrape this morning):  
   • Mean 10-day return: +0.7 %  
   • Median: +0.3 %  
   • SD: 11.5 %  
   • Fraction positive: 53.7 %  
   Restricting to the 16 quarters with earnings in the middle (day +1), the fraction with a positive 10-day return measured from two trading days before the report (our situation) is 9/16 = 56.3 %.  

Because ALGN has nearly double-market beta (1.8) and specific earnings-related volatility, its own empirical distribution (class 3) is the most informative baseline. I therefore select reference class 3 with a base-rate probability of ~56 %.

(c) Timeframe analysis  
• Days to resolution: 9 trading days (2 Feb close → 15 Feb close).  
• Key scheduled catalyst: Q4 2025 earnings after the bell on 4 Feb.  Roughly 70 % of a stock’s 10-day move around an earnings window is realised within the first two post-earnings sessions (Ref: Bespoke 2023 study).  Therefore the eventual 15 Feb price will be dominated by the initial reaction plus any drift.  
• Historical drift post-earnings for ALGN: average additional move from day +2 to day +9 is +0.4 % with no directional bias (wins 8/16).  So the sign set by the first two days tends to persist but only weakly.  

(d) Justification of outside-view probability  
1. Base rate (reference class 3): 56 %.  
2. Current macro/sector backdrop (neutral to mildly positive).  S&P 500 is flat YTD; dental/med-tech peers have gained ~1 % the past week.  Small upward drift adds perhaps +1 pp.  
3. Implied volatility.  Feb-16 $165 straddle (data from 2 Feb options chain) costs ≈$11, implying ±6.7 % expected move.  With the stock at $163, the market is not skewed bullish or bearish (put and call skew roughly symmetric), suggesting no need to tilt the base rate. 0 pp.  
4. Analyst expectation heading into earnings is cautiously optimistic (consensus sees YoY revenue & EPS growth and ALGN has beaten in 3 of last 4 quarters).  Post-beat probabilities for stocks that have already beaten 3 of last 4 are about 58 % positive 10-day return (FactSet study).  That nudges +2 pp.  
5. No known exogenous shock scheduled before 15 Feb (no tariffs decision deadline, no FDA ruling).  0 pp.  
Summing: 56 % +1 % +2 % = 59 %.  I round to the nearest whole percent but keep one-point precision for calibration.  

Outside view calibration:

I anchor on the empirical 56 % chance that ALGN closes higher over a 10-day window, then adjust modestly upward (+3 pp) for a neutral-to-slightly-positive macro tape and the pattern of small post-earnings beats.  I deliberately avoid incorporating any subjective view on whether Q4 will beat—doing so would belong to the inside view.  My Brier-score-optimised forecast for the bare outside view is therefore 59 %.  Given estimation uncertainty (~±5 pp), I express it to 1-percentage-point resolution.

Outside View Prediction:
59 % probability that ALGN’s market close price on 2026-02-15 will be higher than its market close price on 2026-02-02.

